The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.

Tenaya Therapeutics, a US-based heart disease therapy developer leveraging research from University of Texas Southwestern Medical Center and Gladstone Institutes, listed in a $180m initial public offering on the Nasdaq Global Select Market on Thursday. The offering involved the company issuing 12 million shares at $15 each, in the middle of the $14 to $16…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.